Authors
Latest:
The COVID-19 Pandemic Will Have Long-Term Impact on Oncology PracticesThe COVID-19 pandemic created new patient care challenges in oncology, such as how to reduce risks of virus exposure for patients who may be immunocompromised and switching from in-person visits to telemedicine.
Latest:
Dr Advani on the Evaluation of Ribociclib/Endocrine Therapy in HR+/HER2– Breast CancerPooja Advani, MBBS, MD, discusses the use of ribociclib plus endocrine therapy for patients with hormone receptor–positive, HER2– breast cancer.
Latest:
Cleveland Clinic and IBM Researchers Publish Findings on Artificial Intelligence and ImmunityThe study, published in Briefings in Bioinformatics, highlights how artificial intelligence can be designed to develop better immunotherapy treatments.
Latest:
Dr Girda on the Use of Pembrolizumab Plus Chemotherapy in Endometrial CancerEugenia Girda, MD, FACOG, discusses the use of pembrolizumab plus chemotherapy for patients with endometrial cancer as seen in the phase 3 NRG-GY018 trial.
Latest:
HCC International Clinical TrialsClosing the discussion on HCC systemic therapies, Drs Abou-Alfa, Lewandowski and Singal review international clinical trials and access to treatments.
Latest:
Dr. Neumann on Tapering Steroids in cGVHDJoyce L. Neumann, PhD, APRN, AOCN, BMTCN, FAAN, discusses tapering steroids for patients with chronic graft-vs-host disease.
Latest:
Dr Zhou on Ongoing Investigations into the Treatment of Patients With Myelofibrosis and AnemiaAmy W. Zhou, MD, discusses ongoing and planned trials that may enhance therapeutic options for patients with myelofibrosis and anemia that are currently taking place at the Washington University School of Medicine in St. Louis.
Latest:
Question and Answer SessionDr Gary Ulaner and Dr Jeremy Force answer questions submitted by attendees of the live webinar discussing the role of various strategies to detect estrogen receptor (ER)-positive breast cancer, with particular focus on the role of 18-F FES-PET imaging in diagnosis and treatment of ER-positive breast cancer.
Latest:
Dr Mastroyannis on the Continued Investigation of Targeted Therapies in Ovarian CancerS. Alex Mastroyannis, MD, MSCE, discusses the management of gynecologic cancers, such as metastatic or recurrent ovarian and endometrial cancers.
Latest:
Women in Oncology: Prioritization and Passionate LegaciesSelina M. Luger, MD, FRCPC, Gail J. Roboz, MD, and Wendy Stock, MD, discuss how being female affected their careers and share the scientific achievements they most want to be remembered for in the leukemia field.
Latest:
Dr Facon on the Implications of Isatuximab Plus VRd in Transplant-Ineligible Newly Diagnosed MyelomaThierry Facon, MD, discusses clinical implications from the phase 3 IMROZ trial
Latest:
Dr Hartwich on Preclinical Findings for Y3 Plus Chemotherapy in Ovarian CancerYang Yang Hartwich, PhD discusses a study delving into the mechanisms underlying chemoresistance in ovarian cancer.
Latest:
Dr. Finn on the Utility of Belantamab Mafodotin in Late Relapsed Multiple MyelomaLaura Finn, MD, discusses the utility of belantamab mafodotin-blmf in late relapsed multiple myeloma.
Latest:
First-Line Therapy in Advanced Clear Cell RCC: Novel Doublet RegimensAn expert panel reviews novel first-line doublet therapies being studied in patients with advanced clear cell renal cell carcinoma.
Latest:
Dr. Ryan on the Efficacy of Ibrutinib Plus Obinutuzumab in Relapsed/Refractory CLLChristine Ryan, MD, discusses the significance of data for ibrutinib plus obinutuzumab in relapsed/refractory chronic lymphocytic leukemia.
Latest:
Dr. Padia on the Utility of Y-90 Glass Microspheres in HCCSiddharth Padia, MD, discusses the utility of TheraSphere™ Yttrium-90 Glass Microspheres in patients with hepatocellular carcinoma.
Latest:
Closing Thoughts on the MDS Treatment LandscapeFollowing its comprehensive discussion on the treatment of MDS, the expert panel concludes with thoughts on the overall treatment landscape.
Latest:
Looking Ahead: Unmet Needs in AML ManagementA look at emerging treatments and remaining unmet needs in the overall treatment landscape for acute myeloid leukemia.
Latest:
Robotic Navigational Bronchoscopy Advances Diagnosis of Early-Stage Lung CancerNathaniel Ivanick, MD, FCCP, explains advancements in the use of robotic navigational bronchoscopy for the diagnosis of early-stage lung cancer.
Latest:
Building Upon ScaffoldsCancer care is changing rapidly, and understanding and incorporating new practices is challenging both for practicing oncologists and oncology trainees.
Latest:
Dr. Sereti on Addressing an Unmet Need With NOV202/Olaparib in BRCA1/2-Mutated Prostate CancerEvangelia Sereti, MSc, PhD, discusses the unmet need addressed with the addition of NOV202 to olaparib in BRCA1/2-mutated prostate cancer.
Latest:
Dr Hanna on the FDA Approval of Toripalimab in Nasopharyngeal CarcinomaGlenn J. Hanna, MD, discusses the significance of the FDA approval of toripalimab for patients with recurrent or metastatic nasopharyngeal carcinoma.
Latest:
Dr Basu on the Potential Utility of MRD-Guided Adjuvant Therapy in RCCArnab Basu, MD, MPH, FACP, discusses the phase 2 MRD Gate RCC trial of molecular residual disease–guided adjuvant therapy in in renal cell carcinoma.
Latest:
Risk- and Response-Adaptive Strategies Illuminate New Directions for Multiple MyelomaAlthough cytogenetic abnormalities have helped to characterize prognosis and identify patients who are at high risk of early progression, risk stratification has little effect on management decisions for most patients with multiple myeloma.
Latest:
Dr Dhanji on Hypertension as a Risk Factor for Mortality in Urothelial CancerSohail Dhanji, MD, discusses the investigation of preoperative hypertension as a risk factor in patients undergoing nephroureterectomy for upper tract urothelial carcinoma, as well as other risk factors for mortality in this patient population.
Latest:
Dr Scalici on Data for IMNN-001 Plus SOC Chemotherapy in Advanced Ovarian CancerJennifer Scalici, MD, discusses data for IMNN-001plus chemotherapy in advanced ovarian cancer.
Latest:
Next-Generation Sequencing Minimal Residual Disease Testing in Blood Cancer Is Needed Now More Than EverSponsored Content by Adaptive Biotechnologies
Latest:
Dr. Hahn on the Impact of Trastuzumab Emtansine in HER2+ Breast CancerOlwen Hahn, MD, discusses the impact of trastuzumab emtansine on the treatment of patients with HER2-positive breast cancer.
Latest:
Unmet Needs and the Future of HER2+ Breast Cancer TreatmentThe panel closes their discussion by summarizing the most exciting recent advances in HER2+ breast cancer, the future of treatment, and unmet needs that must be addressed.
.jpg?fit=crop&auto=format)
